1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)

被引：0
|
作者：
Guillermo E. Umpierrez
Federico P. Manghi
Santiago Tofe Povedano
Linda Shurzinske
Valeria Pechtner
机构：
来源：
Nederlands Tijdschrift voor Diabetologie | 2013年 / 11卷 / 3期
关键词：
D O I：
10.1007/s12467-013-0030-x
中图分类号：
学科分类号：
摘要：
This Phase 3, randomized, double-blind, parallel-arm, monotherapy study compared the efficacy and safety of 2 doses of dulaglutide (DU), a long-acting GLP-1-receptor agonist, to metformin (MET) in patients with early type 2 diabetes (mean 2.6 years) treated with diet and exercise alone or in combination with 1 oral antidiabetic medication (low dose for ≥ 3 months before screening).
引用
收藏
页码：78 / 78
相关论文
共 50 条
  • [1] Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3)
    Umpierrez, Guillermo E.
    Manghi, Federico P.
    Povedano, Santiago Tofe
    Shurzinske, Linda
    Pechtner, Valeria
    DIABETES, 2013, 62 : A17 - A17
  • [2] Efficacy and safety of dulaglutide vs metformin in type 2 diabetes (AWARD-3)
    Tofe Povedano, S.
    Umpierrez, G.
    Perez Manghi, F.
    Shurzinske, L.
    Pechtner, V.
    DIABETOLOGIA, 2013, 56 : S8 - S8
  • [3] Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
    Umpierrez, Guillermo
    Tofe Povedano, Santiago
    Perez Manghi, Federico
    Shurzinske, Linda
    Pechtner, Valeria
    DIABETES CARE, 2014, 37 (08) : 2168 - 2176
  • [4] Patient-Reported Outcomes With Dulaglutide vs. Metformin (AWARD-3)
    Reaney, Matthew
    Mitchell, Beth D.
    Wang, Ping
    Pechtner, Valeria
    Curtis, Brad
    Van Brunt, Kate
    DIABETES, 2013, 62 : A264 - A264
  • [5] Efficacy and Safety of Once-Weekly Dulaglutide vs. Insulin Glargine in Combination with Metformin and Glimepiride in Type 2 Diabetes Patients (AWARD-2)
    Giorgino, Francesco
    Benroubi, Maria
    Sun, Jui-Hung
    Zimmermann, Alan G.
    Pechtner, Valeria
    DIABETES, 2014, 63 : A87 - A87
  • [6] Safety and Efficacy of Dulaglutide vs. Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5)
    Weinstock, Ruth S.
    Umpierrez, Guillermo E.
    Guerci, Bruno
    Nauck, Michael A.
    Boleyn, Karen L.
    Skrivanek, Zachary
    Milicevic, Zvonko
    DIABETES, 2013, 62 : A258 - A258
  • [7] Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 Diabetes (AWARD-5)
    Nauck, Michael A.
    Weinstock, Ruth S.
    Umpierrez, Guillermo E.
    Guerci, Bruno
    Boleyn, Karen
    Skrivanek, Zachary
    Milicevic, Zvonko
    DIABETES, 2013, 62 : A18 - A18
  • [8] Efficacy and safety of once weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2)
    Giorgino, F.
    Benroubi, M.
    Sun, J. -H.
    Zimmermann, A. G.
    Pechtner, V.
    DIABETOLOGIA, 2014, 57 : S22 - S22
  • [9] 1.7 Efficacy and Safety of Dulaglutide vs. Sitagliptin after 52 Weeks in Type 2 diabetes (AWARD-5) (71-OR)
    Michael A. Nauck
    Ruth S. Weinstock
    Guillermo E. Umpierrez
    Bruno Guerci
    Karen L. Boleyn
    Zachary Skrivanek
    Zvonko Milicevic
    Nederlands Tijdschrift voor Diabetologie, 2013, 11 (3) : 79 - 80
  • [10] Efficacy and safety of dulaglutide vs sitagliptin after 52 weeks in type 2 diabetes (AWARD5)
    Nauck, M. A.
    Weinstock, R. S.
    Umpierrez, G.
    Guerci, B.
    Boleyn, K.
    Skrivanek, Z.
    Milicevic, Z.
    DIABETOLOGIA, 2013, 56 : S368 - S368
12345